Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Shareholders rebuke Bayer bosses over Monsanto-linked stock rout

Published 27/04/2019, 01:42
Updated 27/04/2019, 01:42
© Reuters. German drug and crop chemical maker Bayer holds annual general meeting

© Reuters. German drug and crop chemical maker Bayer holds annual general meeting

By Ludwig Burger

BONN (Reuters) - Bayer (DE:BAYGN) shareholders on Friday cast a vote of disapproval of the German drugmaker's top management amid anger over a stock price slump as litigation risks mount from the $63 billion (48.7 billion pounds) takeover of seed maker Monsanto (NYSE:MON).

A 55.5 percent majority of shareholders at its annual general meeting voted against ratifying the executive board's business conduct during 2018, the company said.

Such a vote, which features prominently at every German AGM, is largely symbolic because it has no bearing on management's liability or tenure but it is seen as a key gauge of investor sentiment.

Bayer's non-executive supervisory board, in turn, won a 66.4 percent majority of the votes ratifying its business conduct during 2018, the spokesman said.

About 30 billion euros ($34 billion) have been wiped off Bayer's market value since August, when a U.S. jury found the pesticide and drugs group liable because Monsanto had not warned of alleged cancer risks linked to its weedkiller Roundup.

Bayer suffered a similar defeat last month, while more than 13,000 plaintiffs are claiming damages.

Bayer is appealing or plans to appeal the verdicts and has pointed to global regulators' findings that the use of glyphosate, the active ingredient in Roundup, is safe.

No incumbent executive board members at companies listed in Germany's blue-chip index DAX has flunked the vote, meaning receiving an approval vote of less than 50 percent at an AGM. Approval rates above 95 percent are typical results.

In a recent low for a company leadership team, former Deutsche Bank (DE:DBKGn) co-CEOs Anshu Jain and Juergen Fitschen scored approval ratings of about 61 percent during the bank's 2015 AGM. Both announced their resignation within weeks.

Top 20 Bayer investors who earlier on Friday said they would cast a 'no' vote included Deka Investment and Union Investment.

"The vote is a disgrace. To be gambling away the trust of so many investors within such a short time has historic proportions," said Ingo Speich, head of sustainability and corporate governance at Deka Investment.

He added he hoped management will listen more to shareholders in future.

This month, shareholder advisory firms Institutional Shareholder Services (ISS) and Glass Lewis recommended that investors not give the executive board their seal of approval.

Earlier on Friday, various shareholders vented their anger at the AGM.

CEO Baumann said Bayer's true value was not reflected in the current share price.

© Reuters. German drug and crop chemical maker Bayer holds annual general meeting

"There's no way to make this look good. The lawsuits and the first verdicts weigh heavily on our company and it's a concern for many people," he said, adding it was the right decision to buy Monsanto and that Bayer was vigorously defending itself.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.